Retatrutide is an investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. It is being developed to treat obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD). By acting on all three receptors, it aims to enhance insulin sensitivity, reduce appetite, increase energy expenditure, and promote significant weight loss and metabolic improvement. It is administered as a once-weekly injection and is currently in clinical trials (as of 2025).
